Home  |  Contact

Cellosaurus LA-N-5 (CVCL_0389)

[Text version]

Cell line name LA-N-5
Synonyms LAN-5; Lan-5; LAN5; Lan5; NBLAN5T
Accession CVCL_0389
Resource Identification Initiative To cite this cell line use: LA-N-5 (RRID:CVCL_0389)
Comments Doubling time: ~100 hours (DSMZ).
Omics: Deep RNAseq analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Miscellaneous: On the basis that LA-350 (CVCL_AR50) and LA-N-5 are both established by Seeger R.C., that they share identical STR profiles and that LA-350 is said to originate from a patient suffering from neuroblastoma we have annotated them as being autologous cell lines.
Misspelling: LAN-3; In Cosmic 920242.
Sequence variations ALK p.Arg1275Gln (c.3824G>A) (ClinVar=VCV000018083) (PubMed=18724359; PubMed=28350380).
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Derived from metastatic site: Bone marrow.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_AR50 ! LA-350
Sex of cell Male
Age at sampling 4M
Category Cancer cell line
STR profile Source(s): COG; DSMZ; RCB

Markers:
AmelogeninX,Y
CSF1PO10 (COG)
10,11 (DSMZ; RCB)
D2S133819,25
D3S135815,16
D5S81811
D7S82010
D8S117911,13
D13S3179,12
D16S5399,12 (COG; RCB)
9 (DSMZ)
D18S5117,22
D19S43313,15
D21S1129,31
FGA21,27
TH016,9.3
TPOX8
vWA15,16

Run an STR similarity search on this cell line
Web pages http://www.cogcell.org/dl/NB_Data_Sheets/LA-N-5_Cell_Line_Data_Sheet_COGcell_org.pdf
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/l/cell-lines-detail-481.html
Publications

PubMed=6172518
Seeger R.C., Danon Y.L., Rayner S.A., Hoover F.
Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody.
J. Immunol. 128:983-989(1982)

DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=18724359; DOI=10.1038/nature07261
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=18923524; DOI=10.1038/nature07399
Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S.
Oncogenic mutations of ALK kinase in neuroblastoma.
Nature 455:971-974(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=23202128; DOI=10.1038/ng.2493
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

Cross-references
Cell line collections DSMZ; ACC-673
ICLC; HTL96022 - Discontinued
NCBI_Iran; C613
RCB; RCB0485
Cell line databases/resources CLDB; cl3170
CLDB; cl3171
LINCS_LDP; LCL-1987
Lonza; 1157
Ontologies BTO; BTO:0000935
CLO; CLO_0007242
CLO; CLO_0050264
MCCL; MCC:0000284
Biological sample resources BioSample; SAMN03472329
BioSample; SAMN03473428
Gene expression databases ArrayExpress; E-MTAB-783
GEO; GSM313804
GEO; GSM333799
GEO; GSM692871
GEO; GSM2371239
GEO; GSM2394369
Other Wikidata; Q54901878
Polymorphism and mutation databases Cosmic; 801742
Cosmic; 920242
Cosmic; 923828
Cosmic; 930066
Cosmic; 947705
Cosmic; 1037345
Cosmic; 1099142
Cosmic; 1109122
Cosmic; 1153783
Cosmic; 1161992
Cosmic; 1167989
Cosmic; 1212538
Cosmic; 1518068
Cosmic; 1526629
Cosmic; 1890201
Cosmic; 2131580
Cosmic; 2239462
Cosmic; 2301576
Cosmic; 2393636
Entry history
Entry creation04-Apr-2012
Last entry updated02-Jul-2020
Version number27